Navigation Links
Volcano Corporation Announces the Relocation of Corporate Headquarters to San Diego
Date:10/6/2008

eceiving its initial venture funding seven years ago into a global public company with market capitalization of approximately $750 million as of Friday, October 3, 2008. Attracting and retaining talented people has always been a priority for Volcano and will be the single most important contributor to Volcano's success during our next stage of growth." Mr. Huennekens added, "The pool of high performing marketing, engineering, finance, and clinical/regulatory professionals in Southern California and San Diego specifically should complement our existing core of talented personnel around the world. Additionally, our ability to work closely with leading interventional cardiology research institutions in Southern California, such as Scripps, UCSD, and Cedars Sinai, is a huge positive as we develop and bring new products to the market."

"Volcano's culture is characterized by an energetic, entrepreneurial, collaborative and fun environment which fits with the fabric and atmosphere of San Diego. We think our culture will flourish here and will help us continue to fuel advancements to help patients and physicians and grow as a company," said Vince Burgess, Executive Vice President of Marketing and Business Development for Volcano.

About Volcano

Volcano offers a broad suite of medical devices designed to facilitate endovascular procedures in the coronary and peripheral arteries, enhance the diagnosis of heart disease and guide optimal less invasive therapies to patients. Since its inception, the company's products have been used in over half a million patients. The company's intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into any modern cath lab. Volcano IVUS offers unique features, including both single-use phased array and rotational IVUS imaging catheters, and advanced functionality options such as VH(R) IVUS tissue characterization. Volcano's IVUS catheters are essentially miniaturized ultraso
'/>"/>

SOURCE Volcano Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Volcano Presentation at Canaccord Adams Conference to be Webcast
2. Volcano Corporation Presentation at JMP Conference to be Webcast
3. Chilean volcano captured blasting ash
4. Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent
5. Volcano Corporation Selects Xactly to Drive Strategic Sales Performance Management
6. Volcano Corporation Presentation at Piper Jaffray Conference to be Webcast
7. Volcano Reports Record Third Quarter Revenues
8. Volcano Corporation Reports Preliminary Third Quarter 2007 Revenues
9. Volcano Corporation Announces Proposed Public Offering of Common Stock
10. MidSouth eHealth Alliance to Transition to Commercial Software Solution from Informatics Corporation of America
11. Mach One Corporation Enters Letter of Intent
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 2Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 3Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 4Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 5Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 6Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 2Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 3ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 1ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 2ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 3Provocative New Fiction Makes for a Fascinating Fast Paced Read 13713 1Provocative New Fiction Makes for a Fascinating Fast Paced Read 13713 2LiveProcess Implements Emergency Management Platform with 51 Florida Hospitals 55482 1LiveProcess Implements Emergency Management Platform with 51 Florida Hospitals 55482 2